SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Troponin in early presenters to rule out myocardial infarction.

Lowry, MTH; Doudesis, D; Boeddinghaus, J; Kimenai, DM; Bularga, A; Taggart, C; Wereski, R; Ferry, AV; Stewart, SD; Tuck, C; et al. Lowry, MTH; Doudesis, D; Boeddinghaus, J; Kimenai, DM; Bularga, A; Taggart, C; Wereski, R; Ferry, AV; Stewart, SD; Tuck, C; Koechlin, L; Nestelberger, T; Lopez-Ayala, P; Huré, G; Lee, KK; Chapman, AR; Newby, DE; Anand, A; Collinson, PO; Mueller, C; Mills, NL; High-STEACS Investigators (2023) Troponin in early presenters to rule out myocardial infarction. Eur Heart J, 44 (30). pp. 2846-2858. ISSN 1522-9645 https://doi.org/10.1093/eurheartj/ehad376
SGUL Authors: Collinson, Paul

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview
[img] Microsoft Word (.docx) (Supplementary data) Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB)

Abstract

AIMS: Whether a single cardiac troponin measurement can safely rule out myocardial infarction in patients presenting within a few hours of symptom onset is uncertain. The study aim was to assess the performance of troponin in early presenters. METHODS AND RESULTS: In patients with possible myocardial infarction, the diagnostic performance of a single measurement of high-sensitivity cardiac troponin I at presentation was evaluated and externally validated in those tested ≤3, 4-12, and >12 h from symptom onset. The limit-of-detection (2 ng/L), rule-out (5 ng/L), and sex-specific 99th centile (16 ng/L in women; 34 ng/L in men) thresholds were compared. In 41 103 consecutive patients [60 (17) years, 46% women], 12 595 (31%) presented within 3 h, and 3728 (9%) had myocardial infarction. In those presenting ≤3 h, a threshold of 2 ng/L had greater sensitivity and negative predictive value [99.4% (95% confidence interval 99.2%-99.5%) and 99.7% (99.6%-99.8%)] compared with 5 ng/L [96.5% (96.2%-96.8%) and 99.3% (99.1%-99.4%)]. In those presenting ≥3 h, the sensitivity and negative predictive value were similar for both thresholds. The sensitivity of the 99th centile was low in early and late presenters at 71.4% (70.6%-72.2%) and 92.5% (92.0%-93.0%), respectively. Findings were consistent in an external validation cohort of 7088 patients. CONCLUSION: In early presenters, a single measurement of high-sensitivity cardiac troponin I below the limit of detection may facilitate the safe rule out of myocardial infarction. The 99th centile should not be used to rule out myocardial infarction at presentation even in those presenting later following symptom onset.

Item Type: Article
Additional Information: © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Keywords: Cardiac troponin, Myocardial infarction, Symptoms, Male, Humans, Female, Troponin I, Biomarkers, Myocardial Infarction, Predictive Value of Tests, Troponin T, Emergency Service, Hospital, High-STEACS Investigators, Humans, Myocardial Infarction, Troponin I, Troponin T, Predictive Value of Tests, Emergency Service, Hospital, Female, Male, Biomarkers, Symptoms, Myocardial infarction, Cardiac troponin, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J
ISSN: 1522-9645
Language: eng
Dates:
DateEvent
7 August 2023Published
23 June 2023Published Online
24 May 2023Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
Projects:
Project IDFunderFunder ID
RG/16/10/32375British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
CH/09/002British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
RE/18/5/34216British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
MR/W000598/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDWellcome Trusthttp://dx.doi.org/10.13039/100004440
SP/12/10/29922British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
MR/N013166/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDDepartment of Healthhttp://dx.doi.org/10.13039/501100000276
UNSPECIFIEDChief Scientist Officehttp://dx.doi.org/10.13039/501100000589
CH/F/21/90010British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
RG/20/10/34966British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
WT103782AIAWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 37350492
Web of Science ID: WOS:001029452300001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115705
Publisher's version: https://doi.org/10.1093/eurheartj/ehad376

Actions (login required)

Edit Item Edit Item